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Abstract
Background: Nonelderly patients may require hospitalization if their symptoms of influenza are severe. However,
little evidence is available about the risk factors for hospitalization for influenza.
Methods: We used a multicenter outpatient and inpatient database to obtain patients’ characteristics and clinical
procedures. We identified patients aged <65 years with a confirmed diagnosis of influenza between October 2013
and December 2014. We used a Cox regression model to identify the risk factors for hospitalization, using a
comparison group of individuals with a confirmed diagnosis of influenza but who were not hospitalized.
Results: Of 88,054 patients diagnosed with influenza, 276 (0.3 %) patients were hospitalized. With reference to
patients aged 18–64 years, the hazard ratio (95 % confidence interval) for hospitalization in patients aged <2, 2–4,
and 5–17 years was 12.25 (8.37–17.93), 4.56 (3.10–6.72) and 1.45 (1.03–2.05), respectively. Anemia, chronic
obstructive pulmonary disease, neurologic disease, and regular steroid use were significantly associated with
hospitalization. Hazard ratios were adjusted for age, sex, comorbidities, respiratory co-infection, virus type, and
influenza season.
Conclusions: Our findings suggest that younger age and several comorbidities are associated with higher
probability of hospitalization for influenza.
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WHO, World Health Organization; WHO-ATC, World Health Organization Anatomical Therapeutic Chemical
Background
Seasonal influenza is a vaccine-preventable disease that
imposes a substantial burden on the global population
every year. The disease is estimated to affect 5–10 % of
adults and 20–30 % of children, and causes severe illness
in 3 million to 5 million patients worldwide each year
[1]. Owing to the rarity of fatal cases [2], especially in
nonelderly patients, hospitalization for influenza has
been the main focus of several studies [3] to make deci-
sions about resource planning, such as stockpiling of
medicines, and to decrease the impact of influenza on
public health. For example, a previous study estimated
the number of hospitalizations for influenza in the
United States from national hospital discharge surveil-
lance data, and found that 57 % of all patients requiring
hospitalization for influenza were aged <65 years [3].
Another study estimated that 3.4 % of all critical illness
hospitalizations were attributable to influenza [4, 5].
Data have been lacking on the risk factors for
hospitalization, although individuals at high risk for
complicated influenza have been defined [6]. A system-
atic review in 2013 revealed that the risk factors for
hospitalization for influenza were rarely investigated [6].
A recent study reported that age, underlying illness, and
influenza viral load were strong predictors for
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hospitalization in 424 patients with laboratory-confirmed
influenza who visited emergency departments [7]. An-
other study demonstrated that individuals with pulmonary
disease, dementia, renal disease, or cancer had a higher
likelihood of hospitalization among community-dwelling
elderly people [8].
Hospitalization, which may reflect both the severity of
disease and physicians’ tendency to hospitalize patients,
is considered a measurable outcome for influenza in pa-
tients aged <65 years [2]. However, owing to the lack of
data, few studies have focused on hospitalization for
influenza in nonelderly patients in all clinical settings,
including primary care, emergency department, and hos-
pital admissions. The characteristics of the patients may
be different in these clinical settings, and the risk factors
for hospitalization for influenza in the general popula-
tion remain unknown.
The aims of the present study were (i) to examine
patient demographic characteristics, clinical courses, and
complications, and (ii) to identify risk factors for
hospitalization in patients aged <65 years diagnosed with




For this study, we used the Japan Medical Data Center
(JMDC) database. The JMDC database includes annual
health checkup records and health insurance claims data
for approximately 1.5 million insured individuals in
2013. The majority of the insured individuals are em-
ployees of Japanese companies and their families. The
database includes information about administrative
claims data for clinic visits and hospital admissions.
Diagnoses and drugs are recorded based on Inter-
national Classification of Diseases 10th revision (ICD-
10) codes and World Health Organization Anatomical
Therapeutic Chemical (WHO-ATC) codes, respectively.
The data did not include individual vaccination status.
We referred to a national surveillance report to obtain
information on seasonal trends and circulating influenza
subtypes [9].
Given the anonymous nature of the data, the require-
ment for informed consent was waived. The study was
approved by the Institutional Review Board of The
University of Tokyo.
Case identification and clinical courses
We identified patients aged <65 years diagnosed with in-
fluenza (ICD-10 code: J10) and confirmed by influenza
testing from October 2013 to December 2014. We
excluded data for patients already hospitalized for dis-
eases other than influenza. We examined several comor-
bidities based on outpatient information recorded within
6 months before the diagnosis of influenza, and selected
these comorbidities by reference to a previous publica-
tion [6]. Patients with asthma, diabetes mellitus, and
steroid use were identified by prescription information
using WHO-ATC classification system codes R03 for
asthma, A10 for diabetes mellitus, and H02 for steroid
use. We coded patients who were prescribed oral ste-
roids and took these steroids for >30 days during the
baseline period as those regularly using steroids. ICD-10
codes were used to identify patients with chronic ob-
structive pulmonary disease (COPD) (J41–J44), cardio-
vascular disease (I20–I25, Q20–Q28), cerebrovascular
disease (I60–I69), mental disorder including dementia
(F00–F99), neurologic disease (G00–G99), anemia
(D50–D59, D60–D64), immunodeficiency (D80–D89),
liver disease (K70–K77), malignancy (D00–D09, C00–
C97), and respiratory co-infection (J0, J12-J18 and J2).
Influenza encephalitis and influenza pneumonia were
identified as complications by Japanese text codes.
Japanese medical procedure codes were used to identify
the following medical procedures: dialysis; influenza
diagnosis test; oxygen administration; peripheral oxygen
saturation monitoring; cardiorespiratory monitoring; in-
tubation; ventilation; and admission to intensive care
unit. Saturation monitoring and cardiorespiratory moni-
toring are only recorded when patients are continuously
monitored. We defined patients with fatal outcomes as
those who died within 1 month of the diagnosis of
influenza. We extracted records for prescription of all
available neuraminidase inhibitors in Japan: oseltamivir;
laninamivir; zanamivir; and peramivir. Although it was not
possible to prove causation of neuraminidase inhibitor-
induced adverse drug reactions, we identified entries of the
following ICD-10 codes that coincided with the prescrip-
tion of a neuraminidase inhibitor: T375 for adverse effects
of antiviral drug; K70–K77 with Japanese text including
“drug” for drug-induced hepatic dysfunction; L511 for
Stevens–Johnson syndrome (SJS); and T782 for anaphyl-
axis. We defined October 2013–September 2014 as the
2013/2014 influenza season and October 2014–December
2014 as the 2014/2015 influenza season.
Data analysis
Continuous data are presented as the mean (± standard
deviation, SD), and categorical data are presented as
numbers (proportion). The chi-square test for categor-
ical variables and t-test for continuous variables were
used to compare two groups. We performed a multivari-
able Cox regression analysis to evaluate factors associ-
ated with hospital admission. The comparison group
was individuals diagnosed with influenza but who were
not hospitalized. For patients who had multiple hospital-
izations for influenza during the study period, we only
included the first episode in the analysis. Patients in
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whom the subtype of influenza was not recorded were
excluded from the analysis. Variables with P <0.10 in
univariate analyses at baseline were included as independ-
ent variables in the multivariable analysis. Proportional
hazard assumption was confirmed using a graphical tech-
nique. We conducted a subgroup analysis restricting of in-
dividuals diagnosed with influenza in the 2013/2014
season (from October 2013 to September 2014) to
examine possible effect modification between years.
All statistical analyses were two-tailed and values of P
<0.05 were considered significant. All statistical com-
putations were performed with SPSS version 22 (IBM
SPSS, Armonk, NY).
Results
A total 1,469,320 individuals were observed during
the baseline period, and 153,711 left the cohort in the
following study period. We identified 88,071 patients
aged <65 years diagnosed with influenza and confirmed by
influenza testing. More than 95 % of patients received
rapid influenza diagnosis tests (RIDTs). We subsequently
excluded 17 patients hospitalized before diagnosis of influ-
enza. We analyzed the remaining 88,054 patients, of
whom 276 (0.3 %) patients were hospitalized. During the
study period, four patients had multiple episodes of
hospitalization for influenza. Mean (SD) follow-up
period was 14.0 months (3.0 months) for the entire cohort
and 14.7 months (1.6 months) for patients diagnosed with
influenza. The seasonal peaks and proportions of virus
types in the study population were consistent with na-
tional surveillance data, which observed A(H1N1),
B(Victoria), and B(Yamagata) in the 2013/2014 season,
and A(H3) in the 2014/2015 season.
Table 1 shows the clinical characteristics of the eligible
patients. Age 18 to 64 years was most common in the
hospitalized patients, as well as all comorbidities. Among
the hospitalized patients, there were six (2.2 %) with in-
fluenza encephalitis and six (2.2 %) with influenza pneu-
monia. Although the database did not include causes of
death, one patient died within 1 month of diagnosis after
influenza.
Table 2 shows the clinical practice patterns for influ-
enza in outpatients and hospitalized patients. Some
hospitalized patients were administered a neuraminidase
inhibitor before admission. Neuraminidase inhibitors
were prescribed for >95 % of outpatients and >90 % of
hospitalized patients. Approximately 64 % of hospital-
ized patients did not receive continuous saturation/car-
diorespiratory monitoring or respiratory support in the
initial month of hospitalization; these parameters would
have been used intermittently.
Figure 1 shows the prescription of neuraminidase in-
hibitors in each age category. The highest proportion of
peramivir administration was observed in patients aged
18–64 years, while oseltamivir was predominantly used
in patients aged <4 years (72.7–83.6 %); the proportion
of oseltamivir was lowest in patients aged 5–17 years
(22.6 %). Although there were no recorded adverse ef-
fects of antiviral drugs, one case of SJS, four cases of
drug-induced hepatic dysfunction, and nine cases of ana-
phylaxis coincided with the prescription of neuraminid-
ase inhibitors.
Table 3 shows the results of the multivariable Cox re-
gression analysis for hospitalization. Patients aged <2 years
(hazard ratio (HR), 12.25; 95 % confidence interval (CI),
8.37–17.93; P <0.001), 2–4 years (HR, 4.56; 95 % CI,
3.10–6.72; P < 0.001), and 5–17 years (HR, 1.45; 95 % CI,
1.03–2.05; P = 0.003) were at higher risk of hospitalization.
Comorbidities that had significant associations with
hospitalization were anemia, COPD, neurologic disease,
and regular steroid use. In the subgroup analysis restricted
to patients diagnosed with influenza in the 2013/2014
season, age <5 years, COPD, neurologic disease, and
regular steroid use were significantly associated with
hospitalization (Table 4).
Discussion
To the best of our knowledge, this is the largest study to
have investigated the clinical courses and risk factors for
hospitalization in patients diagnosed with influenza in
all clinical settings. The proportion of hospitalized pa-
tients was 0.3 % in 88,054 patients with test-confirmed
influenza. More than 90 % of patients diagnosed with
influenza were prescribed neuraminidase inhibitors. Pa-
tients aged <17 years were at higher risk of hospitalization
than those aged 18–64 years. Comorbidities identified as
risk factors for hospitalization included anemia, COPD,
neurologic disease, and regular steroid use.
To date, there is no conclusive evidence of the age at
which risk of hospitalization for influenza is highest. We
observed the strongest association between influenza
hospitalization and age <2 years compared with other
child age categories. Interestingly, a previous meta-
analysis reported that children aged <2 years were at
lower risk of hospitalization than children aged 2–17
years, although the investigators judged the grade of the
evidence to be very low due to study heterogeneity and
lack of adjustment for confounding factors [6]. The find-
ings of a more recent meta-analysis focusing on children
chime with our adjusted hazard ratios, identifying the
strongest association between hospitalization and age in
those aged <2 years compared with children in other age
categories [10]. We also found that the risk of
hospitalization after diagnosis of influenza was elevated
in children 2–5 years and 5–17 years, albeit to a lesser
extent than those aged <2 years. Currently, the WHO
and Centers of Disease Control and Prevention recom-
mend that children aged 6 months to 5 years be
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Table 1 Clinical characteristics of patients diagnosed with influenza
Total 2013/2014 season 2014/2015 season
Parameters Non-hospitalized patient Hospitalized patient P Non-hospitalized patient Hospitalized patient P Non-hospitalized patient Hospitalized patient P
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Number of patients 87,778 276 74,101 239 13,677 37
Female, n (%) 39,122 (44.57) 141 (51.09) 0.034 32,896 (44.39) 122 (51.05) 0.045 6226 (45.52) 19 (51.35) 0.585
Age, (years) <0.001 0.00 <0.001
<2 2916 (3.32) 58 (21.01) 2553 (3.45) 56 (23.43) 363 (2.65) 2 (5.41)
2–4 7932 (9.04) 58 (21.01) 6934 (9.36) 48 (20.08) 998 (7.30) 10 (27.03)
5–17 35,066 (39.95) 75 (27.17) 29,397 (39.67) 62 (25.94) 5669 (41.45) 13 (35.14)
18–64 41,864 (47.69) 85 (30.80) 35,217 (47.53) 73 (30.54) 6647 (48.60) 12 (32.43)
Virus type <0.001 0.00 <0.001 0.769
A 54,643 (62.25) 188 (68.12) 41,160 (55.55) 152 (63.60) 13,483 (98.58) 36 (97.30)
B 32,048 (36.51) 78 (28.26) 31,863 (43.00) 77 (32.22) 185 (1.35) 1 (2.70)
Both A and B 1030 (1.17) 10 (3.62) 1021 (1.38) 10 (4.18) 9 (0.07) 0 (0.00)
Unknown 57 (0.06) 0 (0.00) 57 (0.08) 0 (0.00) 0 (0.00) 0 (0.00)
Comorbidity
Asthma 20,631 (23.50) 109 (39.49) <0.001 17,536 (23.66) 99 (41.42) <0.001 3095 (22.63) 10 (27.03) 0.659
COPD 444 (0.51) 8 (2.90) <0.001 382 (0.52) 7 (2.93) <0.001 62 (0.45) 1 (2.70) 0.422
Cardiovascular disease 811 (0.92) 5 (1.81) 0.222 705 (0.95) 5 (2.09) 0.14 106 (0.78) 0 0.00 1.000
Cerebrovascular disease 357 (0.41) 4 (1.45) 0.025 304 (0.41) 3 (1.26) 0.126 53 (0.39) 1 (2.70) 0.352
Diabetes mellitus 811 (0.92) 6 (2.17) 0.065 711 (0.96) 4 (1.67) 0.425 100 (0.73) 2 (5.41) 0.019
Mental disorder 4294 (4.89) 25 (9.06) 0.002 3618 (4.88) 22 (9.21) 0.003 676 (4.94) 3 (8.11) 0.612
Neurologic disease 4425 (5.04) 33 (11.96) <0.001 3708 (5.00) 26 (10.88) <0.001 717 (5.24) 7 (18.92) 0.001
Anemia 1749 (1.99) 15 (5.43) <0.001 1458 (1.97) 12 (5.02) 0.002 291 (2.13) 3 (8.11) 0.052
Immunodeficiency 113 (0.13) 1 (0.36) 0.811 97 (0.13) 1 (0.42) 0.741 16 (0.12) 0 0.00 1.000
Liver disease 1768 (2.01) 11 (3.99) 0.035 1494 (2.02) 6 (2.51) 0.755 274 (2.00) 5 (13.51) <0.001
Dialysis 19 (0.02) 1 (0.36) 0.08 14 (0.02) 1 (0.42) 0.039 5 (0.04) 0 0.00 1.000
Malignancy 547 (0.62) 6 (2.17) 0.004 464 (0.63) 4 (1.67) 0.102 83 (0.61) 2 (5.41) 0.008
Regular steroid use 796 (0.91) 8 (2.90) 0.002 665 (0.90) 7 (2.93) 0.003 131 (0.96) 1 (2.70) 0.808
Complication
Respiratory co-infection 59,597 (67.90) 201 (72.83) 0.092 50,589 (68.27) 177 (74.06) 0.064 9008 (65.86) 24 (64.86) 1.000
Encephalitis 0 (0.00) 6 (2.17) <0.001 0 (0.00) 6 (2.51) <0.001 0 (0.00) 0 (0.00) –
Pneumonia 0 (0.00) 6 (2.17) <0.001 0 (0.00) 4 (1.67) <0.001 0 (0.00) 2 (5.41) <0.001
Death 0 (0.00) 1 (0.36) <0.001 0 (0.00) 1 (0.42) <0.001 0 (0.00) 0 (0.00) –














vaccinated against influenza. Considering the potential
harm and restricted use of antivirals for patients aged 5–
17 years in current practice [11], inclusion of this age cat-
egory in vaccination recommendations may help avoid
hospital admission for influenza.
Although a previous meta-analysis reported any chronic
lung disease as a risk factor for hospitalization without
discriminating between asthma and COPD [6], we
observed that only COPD was a significant risk for
hospitalization. In addition to the different categorization
of pulmonary diseases, this inconsistency may be partially
attributable to another methodological differences: the as-
sessment in the previous study was unadjusted, whereas
ours was adjusted for multiple factors. We also found that
anemia, COPD, neurologic disease, and regular steroid
use were significant risk factors for hospitalization for in-
fluenza. These findings are broadly comparable with those
of previous studies [1, 12]. Further targeting of individuals
with these risk factors for influenza vaccination may help
minimize their suffering, the economic impact caused by
hospitalization, and potential exacerbation of the under-
lying medical condition.
We observed that >90 % of patients diagnosed with in-
fluenza were prescribed neuraminidase inhibitors. A re-
cent meta-analysis showed that oseltamivir alleviated the
symptoms of influenza in children [13]. In the present
study, the proportion of oseltamivir use was lowest in pa-
tients aged 5–17 years. In current practice in Japan, oselta-
mivir is not recommended for children aged >10 years
because of a report in 2005 describing an association with
neuropsychiatric adverse effects in adolescents [14], des-
pite the fact that the relationship between those events
and oseltamivir was unclear and a conclusive judgment
about causation could not be made [15]. Oseltamivir is
currently the only neuraminidase inhibitor that can be ad-
ministered orally to patients with underlying respiratory
disease, because laninamivir and zanamivir are adminis-
tered as inhaled powders and have the potential to reduce
the forced expiratory volume in 1 second [16]. In addition,
peramivir is not recommended for use in outpatients [14].
Because there is little available evidence on the effects of
oseltamivir on hospital admission in children [13], further





No. % No. %
Number of patients 87,778 276
Neuraminidase inhibitora
Oseltamivir 29,729 (33.87) 70 (25.36)
Laninamivir 35,014 (39.89) 27 (9.78)
Zanamivir 14,788 (16.85) 15 (5.43)
Peramivir 2563 (2.92) 87 (31.52)
Combinations 2149 (2.45) 58 (21.01)
None 3535 (4.03) 19 (6.88)
Procedures
Oxygen administration 43 (15.58)
Saturation monitoring 71 (25.72)
Cardiorespiratory monitoring 59 (21.38)
ICU admission 1 (0.36)
None of above 177 (64.13)
aFor hospitalized patients, neuraminidase inhibitors prescribed before
admission are included
Fig. 1 Prescription patterns of neuraminidase inhibitors
Ono et al. BMC Public Health  (2016) 16:922 Page 5 of 8
conclusive studies will be needed to examine the clinical
benefits and potential harm of oseltamivir for children
aged ≥10 years.
Our study had several limitations. First, the data did
not include day of symptom onset, severity of influenza,
pregnancy, socioeconomic status, or vaccination status.
Owing to the lack of information on vaccination status,
the results potentially underestimated the impacts of
well-known risk factors, including severe cardiovascular
disease, renal failure, pulmonary disease including
asthma, and extreme age, because individuals with these
risk factors were likely to have been vaccinated. Cur-
rently, the Japanese government only subsidizes influ-
enza vaccination for individuals aged ≥65 years and
those aged ≥60 years with chronic disease. Vaccination
coverage in other populations is not fully understood,
but was reportedly 59.2 % in children aged <13 and
28.6 % in individuals aged 13–64 years in the 2010–11
season [17]. Another study that investigated 2935 Japa-
nese individuals with asthma reported that 63.6 % were
vaccinated in the 2011–12 influenza season [18]. Thus,
no significant association between hospitalization and
other well-known risk factors, including asthma may
have been affected by influenza vaccination. On the
other hand, despite high vaccination coverage among
children, it is notable that age <17 years was still identi-
fied as a risk for hospitalization in our study. Second,
the results may have been affected by the exclusion of
patients with false-negative results in RIDTs because the
test was reported to have a specificity of approximately
60 % [19]. Third, the generalizability of our findings may
be limited because accessibility to medical care may be
higher in Japan than other countries, because of Japan’s
universal healthcare system. Also, our study population
Table 3 Results of Cox regression analysis for hospitalization in patients diagnosed with influenza
Univariate Analysis Multivariable analysis
HR 95.0 % CI P HR 95.0 % CI P
Female 1.30 1.03 to 1.65 0.029 1.26 0.99 to 1.59 0.059
Age, (years)
18–64 Ref. <0.001 Ref. <0.001
<2 9.69 6.94 to 13.53 <0.001 12.25 8.37 to 17.93 <0.001
2–4 3.58 2.56 to 5.00 <0.001 4.56 3.10 to 6.72 <0.001
5–17 1.05 0.77 to 1.43 0.757 1.45 1.03 to 2.05 0.033
Comorbidity
Asthma 2.12 1.66 to 2.70 <0.001 1.15 0.88 to 1.51 0.309
COPD 5.79 2.87 to 11.70 <0.001 3.71 1.75 to 7.88 0.001
Cerebrovascular disease 3.59 1.34 to 9.64 0.011 2.48 0.88 to 6.97 0.084
Diabetes mellitus 2.37 1.05 to 5.32 0.037 2.18 0.92 to 5.19 0.076
Mental disorder 1.93 1.28 to 2.92 0.002 1.41 0.89 to 2.25 0.144
Neurologic disease 2.56 1.78 to 3.68 <0.001 2.62 1.68 to 4.11 <0.001
Anemia 2.82 1.67 to 4.74 <0.001 1.90 1.09 to 3.31 0.024
Liver disease 2.02 1.10 to 3.69 0.023 1.47 0.76 to 2.83 0.255
Dialysis 16.09 2.26 to 114.66 0.006 5.87 0.77 to 44.89 0.088
Malignancy 3.53 1.57 to 7.93 0.002 2.29 0.96 to 5.43 0.061
Regular steroid use 3.22 1.60 to 6.51 0.001 2.35 1.12 to 4.91 0.024
Respiratory co-infection 1.26 0.97 to 1.65 0.082 1.06 0.81 to 1.38 0.689
Virus type
A Ref. <0.001 Ref. 0.002
B 0.71 0.54 to 0.92 0.009 0.73 0.55 to 0.96 0.025
Both A and B 2.80 1.48 to 5.28 0.002 2.21 1.16 to 4.22 0.016
Season
2013/2014 Ref. Ref.
2014/2015 0.83 0.59 to 1.17 0.283 0.82 0.57 to 1.17 0.267
COPD chronic obstructive pulmonary disease
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does not completely reflect that of Japan as a whole, as
our cohort comprised employees of Japanese companies
with health insurance and their families; the cohort did
not include unemployed adults. In addition, A (H1N1),
A (H3), B (Victoria), and B (Yamagata) were the most
frequently observed subtypes of influenza virus during
the study period, and the results may not be able to be
extrapolated to other strains of influenza virus. In fact,
our results indicated possible effect modification be-
tween influenza seasons likely influenced by virus strain,
as the significant association between hospitalization
and ages 5–17 years was absent in the subgroup analysis
that examined only data from the 2013/2014 season. Fi-
nally, because comorbidities recorded in an administra-
tive claims database are generally less accurate than
those in planned prospective studies, potential miscod-
ing of comorbidities may have affected the results if
there was an imbalance of miscoding between hospital-
ized patients and non-hospitalized patients.
Nevertheless, the strength of our study is that we iden-
tified risk factors for hospitalization using a database
that covers a very large number of individuals diagnosed
with influenza in all clinical settings.
Conclusion
In conclusion, we found that people aged <17 years were
at higher risk for hospitalization for influenza than people
aged 18–64 years. Comorbidities as risk factors for
hospitalization were anemia, COPD, neurologic disease,
and regular steroid use. People with these conditions
should be further encouraged to be vaccinated against in-
fluenza as a preventative measure against hospitalization.
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